Daxor (DXR) Price-to-Tangible-Book

: 1.38 (As of Today)

View and export this data going back to 1992. Start your Free Trial

As of today (2024-04-23), Daxor's share price is $9.79. Daxor's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $7.08. Hence, Daxor's Price to Tangible Book Ratio of today is 1.38.

The historical rank and industry rank for Daxor's Price-to-Tangible-Book or its related term are showing as below:

DXR' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.13 Med: 2.04 Max: 3.22
Current: 1.38

During the past 13 years, Daxor's highest Price to Tangible Book Ratio was 3.22. The lowest was 1.13. And the median was 2.04.

DXR's Price-to-Tangible-Book is ranked better than
74.82% of 703 companies
in the Medical Devices & Instruments industry
Industry Median: 2.62 vs DXR: 1.38

A closely related ratio is called PB Ratio. As of today, Daxor's share price is $9.79. Daxor's Book Value per Sharefor the quarter that ended in Dec. 2023 was $7.08. Hence, Daxor's P/B Ratio of today is 1.38.

Daxor Price-to-Tangible-Book Historical Data

The historical data trend for Daxor's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Daxor Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Tangible-Book

2.76

3.22

2.15

1.36

Daxor Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Price-to-Tangible-Book																2.15	2.72	1.36	1.52	1.36

Competitive Comparison

For the Medical Instruments & Supplies subindustry, Daxor's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Daxor Price-to-Tangible-Book Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Daxor's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Daxor's Price-to-Tangible-Book falls into.

Daxor Price-to-Tangible-Book Calculation

Daxor's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Dec. 2023 )
	=	9.79	/	7.076
	=	1.38

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Daxor Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Daxor's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Daxor (DXR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Daxor Corp (NAS:DXR) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

DX5:Germany

Address

109 Meco Lane, Oak Ridge, TN, USA, 37830

Website

https://www.daxor.com

Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. It develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.

Executives

Robert J Michel	officer: CHIEF FINANCIAL OFFICER	C/O ASTA FUNDING, INC., 210 SYLVAN AVENUE, ENGLEWOOD CLIFFS NJ 07632
Michael Richard Feldschuh	director	71 GRAND STREET #2, NEW YORK NY 10013
Joy S. Goudie	director	350 FIFTH AVENUE, SUITE 4740, NEW YORK NY 10118
Caleb Desrosiers	director	DAXOR CORPORATION, 109 MECO LANE, OAK RIDGE TN 37830
Henry D. Cremisi	director	350 FIFTH AVENUE, SUITE 4740, NEW YORK NY 10118
Edward Feuer	director	2 WALL STREET, 10TH FLOOR, NEW YORK NY 10005
Soren Thompson	officer: V.P./BUSINESS DEVELOPMENT	180 CENTRAL PARK SOUTH, APT. 805, NEW YORK NY 10019
Jonathan Adam Feldschuh	director, officer: CHIEF SCIENTIFIC OFFICER	DAXOR CORPORATION, 350 5TH AVENUE, SUITE 4740, NEW YORK NY 10118
Joseph Feldschuh	officer: President	615 W. 252ND STREET, BRONX NY 10471
Estate Of Joseph Feldschuh	other: FOUNDER	350 FIFTH AVENUE, SUITE 4740, NEW YORK NY 10118
Diane Marie Meegan	officer: Corporate Secretary	259 NEW YORK AVENUE, JERSEY CITY NJ 07307
Bernhard Saxe	director	6805 WILD ROSE COURT, SPRINGFIELD VA 25152
Robert Willens	director	200 EAST 74TH ST APT 18C, NEW YORK NY 10021
Philip Nordan Hudson	director	P.O. BOX 160892, SAN ANTONIO TX 78280-3092
Everis Engstrom	officer: Vice President	3244 BLACK FOX ROAD, WASHBURN TN 37888